Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead Sciences 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead Sciences 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences

3Q Revenues: $1.1 billion (+41%)

3Q Earnings: $398 million (net loss of $52 million in 3Q06)

YTD Revenues: $3.1 billion (+47%)

YTD Earnings: $1.2 billion (+155%)

Comments: Sales of new HIV medication Atripla reached $241 million, after posting $68 million in 3Q06. Sales of top product Truvada increased 30% to $409 million. Overall, the HIV franchise was up 45% to $806 million, while non-HIV products Hepsera (hepatitis B) and Ambisome (severe fungal infection) contributed $148 million to 3Q revenues, up from $110 million in 3Q06.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters